1
|
James J, Teo M, Ramachandran V, Law M, Ip E, Cheng M. Looking for Metastasis in Early Breast Cancer: Does Bone Scan Help? A Retrospective Review. Clin Breast Cancer 2020; 21:e18-e21. [PMID: 32950408 DOI: 10.1016/j.clbc.2020.07.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 06/06/2020] [Accepted: 07/06/2020] [Indexed: 01/18/2023]
Abstract
BACKGROUND Routine staging investigations are not recommended for early breast cancer (EBC). Staging scans and further confirmatory tests add to the cost of breast cancer treatment. Despite recommendations from international guidelines, whole body bone scan (BS) is commonly used for staging EBC. We examined our experience with BS as a staging investigation when selectively used in EBC. PATIENTS AND METHODS All EBC patients who underwent treatment through the Eastern Health breast unit during a 50-month period from January 2012 were included in this study. All staging BS results were reviewed to evaluate yield and false-positive rate. The causes of false-positive results were analyzed. The role of BS when performed along with computed tomographic scans of chest, abdomen, and pelvis (CTCAP) was evaluated. RESULTS Even with the selective use of BS, we could only achieve a yield of 1% (95% confidence interval, -0.6, 2.7) in EBC. When combined with CTCAP, only one additional metastasis was detected in 194 BSs. CONCLUSION BS plays only a limited role in staging EBC. Patients who have undergone CTCAP will experience minimal benefit by undergoing additional BS.
Collapse
Affiliation(s)
- Justin James
- Breast and Endocrine Unit, Maroondah Hospital, Eastern Health, Melbourne, Australia; Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, Australia.
| | - Melanie Teo
- Breast and Endocrine Unit, Maroondah Hospital, Eastern Health, Melbourne, Australia
| | | | - Michael Law
- Breast and Endocrine Unit, Maroondah Hospital, Eastern Health, Melbourne, Australia
| | - Eugenia Ip
- Breast and Endocrine Unit, Maroondah Hospital, Eastern Health, Melbourne, Australia
| | - Michael Cheng
- Breast and Endocrine Unit, Maroondah Hospital, Eastern Health, Melbourne, Australia
| |
Collapse
|
2
|
Aristei C, Amichetti M, Ciocca M, Nardone L, Bertoni F, Vidali C. Radiotherapy in Italy after Conservative Treatment of Early Breast Cancer. A Survey by the Italian Society of Radiation Oncology (AIRO). TUMORI JOURNAL 2018; 94:333-41. [DOI: 10.1177/030089160809400308] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and Background The aim of surveys on clinical practice is to stimulate discussion and optimize practice. In this paper the current Italian radiotherapy practice after breast-conserving surgery for early breast cancer is described and adherence to national and international guidelines is assessed. Furthermore, results are compared with an earlier survey in northern Italy and international reports. Study Design A multiple-choice questionnaire sent to all 138 Italian radiation oncology centers. Results 48% of centers responded. Most performed breast-conserving surgery when tumor size was ≤3 cm. All centers routinely performed axillary dissection; 45 carried out sentinel node biopsy followed by axillary dissection when the sentinel node was positive. Most centers re-excised when resection margins were positive. The median interval between surgery and radiotherapy, when chemotherapy was not administered, was 60 days. Adjuvant chemotherapy was preferably administered before radiotherapy. Regional lymph nodes were never irradiated in 10 centers; in all others irradiation depended on the number of positive lymph nodes and/or involvement of axillary fat and/or tumor location in medial quadrants. All centers used standard fractionation; hypofractionated schemes were available in 6. Most centers used 4–6 MV photons. In 59 centers the boost dose of 10 Gy could be increased if margins were not negative. All centers ensured patient setup reproducibility. Treatment planning was computerized in 59 centers. The irradiation dose was prescribed at the ICRU point in 56 centers and portal films were made in 54 centers. Intraoperative radiotherapy was used in 4 centers: for partial breast irradiation in 1 and for boost administration in 3 centers. Conclusions Although the quality of radiotherapy delivery has improved in Italy in recent years, approaches that do not conform to international standards persist.
Collapse
Affiliation(s)
- Cynthia Aristei
- Department of Radiation Oncology, University of Perugia, Perugia
| | | | - Mario Ciocca
- Medical Physics Unit, European Institute of Oncology, Milan
| | - Luigia Nardone
- Department of Radiotherapy, Sacred Heart Catholic University, Rome
| | | | | |
Collapse
|
3
|
McCartan DP, Prichard RS, MacDermott RJ, Rothwell J, Geraghty J, Evoy D, Quinn CM, Skehan SJ, O'Doherty A, McDermott EW. Role of bone scan in addition to CT in patients with breast cancer selected for systemic staging. Br J Surg 2016; 103:839-44. [DOI: 10.1002/bjs.10124] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Revised: 09/04/2015] [Accepted: 01/05/2016] [Indexed: 01/05/2023]
Abstract
Abstract
Background
The majority of women with breast cancer present with localized disease. The optimal strategy for identifying patients with metastatic disease at diagnosis remains unclear. The aim of this study was to evaluate the additional diagnostic yield from isotope bone scanning when added to CT staging of the thorax, abdomen and pelvis (CT-TAP) in patients with newly diagnosed breast cancer.
Methods
All patients diagnosed with breast cancer who underwent staging CT-TAP and bone scan between 2011 and 2013 were identified from a prospective database of a tertiary referral breast cancer centre that provides a symptomatic and population-based screening breast service. Criteria for staging included: biopsy-proven axillary nodal metastases; planned neoadjuvant chemotherapy or mastectomy; locally advanced or inflammatory breast cancer and symptoms suggestive of metastases.
Results
A total of 631 patients underwent staging by CT-TAP and bone scan. Of these, 69 patients (10·9 per cent) had distant metastasis at presentation, with disease confined to a single organ in 49 patients (71 per cent) and 20 (29 per cent) having metastatic deposits in multiple organs. Bone metastasis was the most common site; 39 of 49 patients had bone metastasis alone and 12 had a single isolated metastatic deposit. All but two of these were to the axial skeleton. No preoperative histological factors identified a cohort of patients at risk of metastatic disease. Omission of the bone scan in systemic staging would have resulted in a false-negative rate of 0·8 per cent.
Conclusion
For patients diagnosed with breast cancer, CT-TAP is a satisfactory stand-alone investigation for systemic staging.
Collapse
Affiliation(s)
- D P McCartan
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| | - R S Prichard
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| | - R J MacDermott
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| | - J Rothwell
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| | - J Geraghty
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| | - D Evoy
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| | - C M Quinn
- Department of Pathology, St Vincent's University Hospital, Dublin, Ireland
| | - S J Skehan
- Department of Radiology, St Vincent's University Hospital, Dublin, Ireland
| | - A O'Doherty
- Department of Radiology, St Vincent's University Hospital, Dublin, Ireland
| | - E W McDermott
- Department of Surgery, St Vincent's University Hospital, Dublin, Ireland
| |
Collapse
|
4
|
Abstract
In the US, over 200,000 new cases of invasive breast cancer are diagnosed each year, with an additional 60,000 cases of ductal carcinoma in situ. The majority of these women will never experience a recurrence of their disease, and most will survive more than 5 years. Follow-up care for these women is focused on addressing long-term complications of therapy, and early detection of new primary cancers and locoregional recurrences. There is no evidence that early detection of distant metastases will lead to an increase in survival, and currently routine imaging studies are not recommended. With the growing number of breast cancer survivors, further studies should be undertaken to study the cost-effectiveness of surveillance strategies.
Collapse
Affiliation(s)
- Sara M Tolaney
- Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA.
| | | |
Collapse
|
5
|
Puglisi F, Andreetta C, Fasola G, Cattaruzzi E, Geatti O. Bone Scan for Baseline Staging in Invasive Breast Cancer at the Time of Primary Presentation. Breast Care (Basel) 2007. [DOI: 10.1159/000111546] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
6
|
Lee JE, Park SS, Han W, Kim SW, Shin HJ, Choe KJ, Oh SK, Youn YK, Noh DY, Kim SW. The clinical use of staging bone scan in patients with breast carcinoma: reevaluation by the 2003 American Joint Committee on Cancer staging system. Cancer 2005; 104:499-503. [PMID: 15968691 DOI: 10.1002/cncr.21200] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Using the new 2003 American Joint Committee on Cancer (AJCC) staging system, the authors evaluated the usefulness of the staging bone scan in patients with primary breast carcinoma. METHODS The authors examined 1939 patients with primary breast carcinoma for staging bone scan who were treated at a single institution. Pathologic stage was assigned retrospectively according to the 1988 and the 2003 AJCC staging systems. RESULTS Bone metastasis rates were 0.7% (4 of 586) for patients with Stage I disease, 0.7% (5 of 699) for patients with Stage IIA disease, 2.1% (10 of 479) for patients with Stage IIB disease, 4.5% (7 of 154) for patients with Stage IIIA disease, and 10.5% (2 of 19) for patients with Stage IIIB disease according to the 1988 AJCC staging system. The authors found a significant difference in the bone metastasis rate between patients with Stages IIA and IIB disease in the 1988 staging system (P = 0.039). Reevaluating the patients by the 2003 system resulted in significant upstaging, especially for patients with Stage II/III disease. According to the 2003 staging system, bone metastasis rates were 0.7% (4 of 586) for patients with Stage I disease, 0.6% (4 of 648) for patients with Stage IIA disease, 0.6% (2 of 310) for patients with Stage IIB disease, 4.0% (9 of 225) for patients with Stage IIIA disease, 16.7% (2 of 12) for patients with Stage IIIB disease, and 4.4% (7 of 158) for patients with Stage IIIC disease. It was noteworthy that there was a significant difference between Stages IIB and IIIA in the 2003 staging system (P = 0.010). CONCLUSIONS Stage reclassification using the new AJCC staging system resulted in upstaging of high-risk patients, as well as a significant decrease in the bone metastasis rate in patients with Stage IIB breast carcinoma. Considering the cost-effectiveness of staging bone scan, the data suggested that it was of little value for patients with Stage I and II breast carcinoma, but was highly recommended for patients with worse than Stage III disease by the new 2003 staging system.
Collapse
Affiliation(s)
- Jeong Eon Lee
- Department of Surgery, Seoul National University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
The aim of this retrospective study was to determine the predictors of a positive bone scan in female patients with breast carcinoma. The participants were 126 females with newly diagnosed breast carcinoma and a baseline bone scan. Patients who had started treatment before their bone scan were excluded. Bone scans were assessed as "no metastases" or "definite skeletal metastases" without knowledge of the patient's predictor variables. Those with "possible metastases" were correlated with other available imaging and clinical information, and recategorized as "no metastases" or "definite skeletal metastases". Results were compared with predictor variables. Significant predictors were increasing age, a higher histopathological grading and positive progesterone receptor status following a forward-stepwise logistic regression analysis. Axillary nodal status, tumour size and oestrogen receptor status did not correlate with a positive bone scan. Not every patient needs a staging bone scan. This study is important because it predicts the need for baseline scintigraphy for specific patients in whom skeletal metastases are more likely to be present or to develop. The findings are particularly valuable in times of worldwide resource scarcity and evolving surgical practice.
Collapse
Affiliation(s)
- Y Y Ho
- Department of Diagnostic Imaging, The National University Hospital of Singapore, 5 Lower Kent Ridge Road, Singapore 119074.
| | | |
Collapse
|
8
|
Demicheli R, Bonadonna G, Hrushesky WJM, Retsky MW, Valagussa P. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res 2004; 6:R689-96. [PMID: 15535851 PMCID: PMC1064084 DOI: 10.1186/bcr937] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2004] [Revised: 08/12/2004] [Accepted: 08/31/2004] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Information on the metastasis process in breast cancer patients undergoing primary tumour removal may be extracted from an analysis of the timing of clinical recurrence. METHODS The hazard rate for local-regional and/or distant recurrence as the first event during the first 4 years after surgery was studied in 1173 patients undergoing mastectomy alone as primary treatment for operable breast cancer. Subset analyses were performed according to tumour size, axillary nodal status and menopausal status. RESULTS A sharp two-peaked hazard function was observed for node-positive pre-menopausal patients, whereas results from node-positive post-menopausal women always displayed a single broad peak. The first narrow peak among pre-menopausal women showed a very steep rise to a maximum about 8-10 months after mastectomy. The second peak was considerably broader, reaching its maximum at 28-30 months. Post-menopausal patients displayed a wide, nearly symmetrical peak with maximum risk at about 18-20 months. Peaks displayed increasing height with increasing axillary lymph node involvement. No multi-peaked pattern was evident for either pre-menopausal or post-menopausal node-negative patients; however, this finding should be considered cautiously because of the limited number of events. Tumour size influenced recurrence risk but not its timing. Findings resulting from the different subsets of patients were remarkably coherent and each observed peak maintained the same position on the time axis in all analysed subsets. CONCLUSIONS The risk of early recurrence for node positive patients is dependent on menopausal status. The amount of axillary nodal involvement and the tumour size modulate the risk value at any given time. For pre-menopausal node-positive patients, the abrupt increase of the first narrow peak of the recurrence risk suggests a triggering event that synchronises early risk. We suggest that this event is the surgical removal of the primary tumour. The later, broader, more symmetrical risk peaks indicate that some features of the corresponding metastatic development may present stochastic traits. A metastasis development model incorporating tumour dormancy in specific micro-metastatic phases, stochastic transitions between them and sudden acceleration of the metastatic process by surgery can explain these risk dynamics.
Collapse
Affiliation(s)
| | | | | | - Michael W Retsky
- Department of Surgery, Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | | |
Collapse
|
9
|
Gerber B, Seitz E, Müller H, Krause A, Reimer T, Kundt G, Friese K. Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread. Breast Cancer Res Treat 2003; 82:29-37. [PMID: 14672401 DOI: 10.1023/b:brea.0000003917.05413.ac] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Is a perioperative metastatic screening program indicated in patients presenting with primary operable breast cancer and no signs of distant metastases? PATIENTS AND METHODS The impact of staging results (chest X-ray, bone scanning, liver ultrasound) for prognosis, treatment, quality of life and costs was retrospectively analyzed in 1076 patients with an operable breast cancer and no clinical signs of metastases. RESULTS Staging examinations revealed 30 (2.8%) distant metastases, 130 (12.1%) suspect findings and excluded metastases in 916 (85.1%) patients. Further diagnostic procedures confirmed distant metastases in 7 (5.4%) and excluded them in 123 (94.6%) out of 130 patients with suspect findings. Distant metastases were detected more frequently with increasing pathological tumor size (pT < or = 2.0 cm: 1.6%, pT 2.1-5.0 cm: 3.0%, respectively pT > 5.0 cm: 15.1%; p < 0.001) and increasing number of involved axillary lymph nodes (pN0: 1.9%, pN1-3+: 1.8%, pN4-9+: 4.0%, pN > or = 10+: 18.7%; p < 0.001). Due to false positive findings 123 (11.4%) patients had to live for a significant period of time with the psychological distress of suspected metastatic disease. The abandonment of a perioperative screening in 1076 patients saves costs of at least Euros 259,367.68. CONCLUSIONS In breast cancer patients without clinical signs of tumor spread perioperative screening for metastases is not warranted because of low frequency of metastases, false positive findings, missing therapeutic consequences and high costs.
Collapse
Affiliation(s)
- Bernd Gerber
- Department of Obstetrics and Gynecology, Klinikum Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany.
| | | | | | | | | | | | | |
Collapse
|
10
|
|